KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBITDA Margin (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBITDA Margin for 11 consecutive years, with 856.95% as the latest value for Q1 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 856.95% in Q1 2025 year-over-year; TTM through Dec 2025 was 359.88%, a N/A change, with the full-year FY2025 number at 689.79%, changed N/A from a year prior.
  • EBITDA Margin was 856.95% for Q1 2025 at Xenon Pharmaceuticals, up from 29924.24% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 879.18% in Q4 2021 to a low of 29924.24% in Q3 2022.
  • A 3-year average of 4685.67% and a median of 612.72% in 2025 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: skyrocketed 113011bps in 2021, then crashed -2957762bps in 2022.
  • Xenon Pharmaceuticals' EBITDA Margin stood at 879.18% in 2021, then tumbled by -3504bps to 29924.24% in 2022, then soared by 97bps to 856.95% in 2025.
  • Per Business Quant, the three most recent readings for XENE's EBITDA Margin are 856.95% (Q1 2025), 29924.24% (Q3 2022), and 5655.78% (Q2 2022).